Clean and tidy

Clean and tidy

ID Biomedical Corporation has completed construction of a pilot vaccine manufacturing plant that will allow the Company to produce clinical grade materials in accordance with US Food and Drug Administration Good Manufacturing Practices. The six-room state-of-the-art facility is located adjacent to ID Biomedical's research and development facility near Seattle, Washington. The pilot plant includes a mid-commercial scale fermentation suite capable of producing recombinant proteins, and a downstream processing suite appropriate for protein purification and vaccine formulation. The new facility provides class 10,000 and class 1,000 clean rooms and support systems for manufacturing materials suitable for at least Phase II clinical studies, and for some materials, Phase III Clinical Trials. The ID Biomedical facility was designed and constructed in collaboration with BMW Pilchuck, a highly specialised design/construction group with extensive experience in the development of biopharmaceutical facilities. For more, see http://www.idbiomedical.com